trending Market Intelligence /marketintelligence/en/news-insights/trending/r6lnyc5fpzso0pjwlhyecg2 content esgSubNav
In This List

TG Therapeutics appoints chief commercial officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


TG Therapeutics appoints chief commercial officer

New York-based biopharmaceutical company TG Therapeutics Inc. appointed Adam Waldman as chief commercial officer.

Waldman most recently served as the head of U.S. hematology-oncology marketing at Celgene Corp.

Waldman will help with the launch of TG Therapeutics' products over the next few years. The company is developing two therapies targeting hematological malignancies and autoimmune diseases: ublituximab, or TG-1101, and umbralisib, or TGR-1202.